论文部分内容阅读
研究重组人生长激素(recombinant human growth hormone,rhGH)对生长激素伴促性腺激素缺乏症(growth hor-mone and gonadotropic deficiency)患儿骨矿密度(bone mineral density,BMD)的影响,对10例男性原发性生长激素伴促性腺激素缺乏症患者,平均年龄(15.9±3.1)岁(12.3岁～23.1岁),用单光子吸收法(single photon absorptiometry,SPA)测定桡骨远端1/3处的BMD。患者皆接受rhGH治疗,疗程12个月。分别于治疗前及治疗后6、12月测BMD、身高、骨龄。结果:治疗前患者BMD较正常同龄儿明显低下(P<0.01),治疗6月BMD较治疗前更见下降(P<0.01),治疗12月时上升并高于治疗前基值。身高显著增加(P均<0.01)。提示GHD患者BMD降低,经rhGH替代治疗能予改善。
To investigate the effect of recombinant human growth hormone (rhGH) on bone mineral density (BMD) in children with growth hormone and gonadotropic deficiency, 10 male The patients with primary growth hormone and gonadotropin deficiency had a mean age of (15.9 ± 3.1) years (12.3 to 23.1 years) and single photon absorptiometry (SPA) at 1/3 of the distal radius BMD. Patients were treated with rhGH for 12 months. The BMD, height and bone age were measured before treatment and after 6 and 12 months respectively. Results: The BMD of patients before treatment was significantly lower than that of normal peers (P <0.01). The BMD of patients in treatment group was significantly lower than that before treatment (P <0.01). The BMD increased at 12 months and was higher than that before treatment. Height increased significantly (all P <0.01). Prompted BMD patients with GHD decreased rhGH replacement therapy can be improved.